Early Radiographic Progression of Scleroderma: Lung Disease Predicts Long-term Mortality.
Journal Information
Full Title: Chest
Abbreviation: Chest
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Pulmonary Medicine
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Financial/nonfinancial disclosures: The authors have reported to CHEST the following: E. R. V. reports consulting and speaker fees from Boehringer Ingelheim and grant support from Boehringer Ingelheim, Kadmon and Horizon Therapeutics. D. P. T. reports grant support from 10.13039/100004328Genentech/10.13039/100004337Roche. M. D. R. reports grant support from 10.13039/100004328Genentech/10.13039/100004337Roche. None declared (J. G., G. H. J. K.)."
"FUNDING/SUPPORT: This study was funded by the 10.13039/100000050National Heart, Lung, and Blood Institute , 10.13039/100000002National Institutes of Health [Grants K23 HL150237 (E. R. V.), R01 HL089758 (D. P. T.), R01 HL089901 (see Acknowledgments), U01 HL 60587 (D. P. T.), and U01 HL 60606 (see Acknowledgments). Bristol—Myers Squibb supplied cyclophosphamide for use in Scleroderma Lung Study I and Hoffmann-LaRoche supplied mycophenolate mofetil for use in Scleroderma Lung Study II."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025